HSP90 as a novel molecular target in non-small-cell lung cancer

Khashayar Esfahani, Victor Cohen Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the land...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Esfahani K, Cohen V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Non-small cell lung cancer driver mutations targeted therapy heat shock protein 90 (HSP90) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c825e459e0d84d2aafce3734f4eeb073
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c825e459e0d84d2aafce3734f4eeb073
record_format	dspace
spelling	oai:doaj.org-article:c825e459e0d84d2aafce3734f4eeb0732021-12-02T03:03:03ZHSP90 as a novel molecular target in non-small-cell lung cancer1179-2728https://doaj.org/article/c825e459e0d84d2aafce3734f4eeb0732016-03-01T00:00:00Zhttps://www.dovepress.com/hsp90-as-a-novel-molecular-target-in-non-small-cell-lung-cancer-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Khashayar Esfahani, Victor Cohen Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression. Keywords: non-small-cell lung cancer, driver mutations, targeted therapy, heat shock protein 90 (HSP90)Esfahani KCohen VDove Medical PressarticleNon-small cell lung cancerdriver mutationstargeted therapyheat shock protein 90 (HSP90)Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 11-17 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-small cell lung cancer driver mutations targeted therapy heat shock protein 90 (HSP90) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Non-small cell lung cancer driver mutations targeted therapy heat shock protein 90 (HSP90) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Esfahani K Cohen V HSP90 as a novel molecular target in non-small-cell lung cancer
description	Khashayar Esfahani, Victor Cohen Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression. Keywords: non-small-cell lung cancer, driver mutations, targeted therapy, heat shock protein 90 (HSP90)
format	article
author	Esfahani K Cohen V
author_facet	Esfahani K Cohen V
author_sort	Esfahani K
title	HSP90 as a novel molecular target in non-small-cell lung cancer
title_short	HSP90 as a novel molecular target in non-small-cell lung cancer
title_full	HSP90 as a novel molecular target in non-small-cell lung cancer
title_fullStr	HSP90 as a novel molecular target in non-small-cell lung cancer
title_full_unstemmed	HSP90 as a novel molecular target in non-small-cell lung cancer
title_sort	hsp90 as a novel molecular target in non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/c825e459e0d84d2aafce3734f4eeb073
work_keys_str_mv	AT esfahanik hsp90asanovelmoleculartargetinnonsmallcelllungcancer AT cohenv hsp90asanovelmoleculartargetinnonsmallcelllungcancer
_version_	1718402007823286272

HSP90 as a novel molecular target in non-small-cell lung cancer

Ejemplares similares